Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Mesoblast Limited ( (AU:MSB) ) is now available.
Mesoblast Limited has notified the ASX of a proposed issue of 1,260,589 new ordinary fully paid shares. The company has lodged an Appendix 3B outlining that these securities will be issued as part of a placement or other type of capital raising, with the proposed issue date set for April 7, 2026.
The additional equity issuance signals a move to bolster Mesoblast’s capital base, which may support ongoing operational or strategic initiatives. Existing shareholders face potential dilution of their holdings, while the transaction underscores the company’s continuing reliance on equity markets to fund its growth and development programs.
The most recent analyst rating on (AU:MSB) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited is an Australian-listed biotechnology company focused on developing and commercializing cellular medicines. Its ordinary fully paid shares trade on the ASX under the ticker MSB, giving investors exposure to the company’s activities in advanced therapeutics and related biopharmaceutical development.
Average Trading Volume: 4,142,419
Technical Sentiment Signal: Hold
Current Market Cap: A$2.75B
See more data about MSB stock on TipRanks’ Stock Analysis page.